These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

652 related articles for article (PubMed ID: 31270226)

  • 1. Chikungunya Virus Vaccine Candidates with Decreased Mutational Robustness Are Attenuated
    Carrau L; Rezelj VV; Noval MG; Levi LI; Megrian D; Blanc H; Weger-Lucarelli J; Moratorio G; Stapleford KA; Vignuzzi M
    J Virol; 2019 Sep; 93(18):. PubMed ID: 31270226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel attenuated Chikungunya vaccine candidates elicit protective immunity in C57BL/6 mice.
    Hallengärd D; Kakoulidou M; Lulla A; Kümmerer BM; Johansson DX; Mutso M; Lulla V; Fazakerley JK; Roques P; Le Grand R; Merits A; Liljeström P
    J Virol; 2014 Mar; 88(5):2858-66. PubMed ID: 24371047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutating chikungunya virus non-structural protein produces potent live-attenuated vaccine candidate.
    Chan YH; Teo TH; Utt A; Tan JJ; Amrun SN; Abu Bakar F; Yee WX; Becht E; Lee CY; Lee B; Rajarethinam R; Newell E; Merits A; Carissimo G; Lum FM; Ng LF
    EMBO Mol Med; 2019 Jun; 11(6):. PubMed ID: 31015278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liposomal Delivery of the RNA Genome of a Live-Attenuated Chikungunya Virus Vaccine Candidate Provides Local, but Not Systemic Protection After One Dose.
    Abeyratne E; Tharmarajah K; Freitas JR; Mostafavi H; Mahalingam S; Zaid A; Zaman M; Taylor A
    Front Immunol; 2020; 11():304. PubMed ID: 32194557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutation of the N-Terminal Region of Chikungunya Virus Capsid Protein: Implications for Vaccine Design.
    Taylor A; Liu X; Zaid A; Goh LY; Hobson-Peters J; Hall RA; Merits A; Mahalingam S
    mBio; 2017 Feb; 8(1):. PubMed ID: 28223458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deliberate attenuation of chikungunya virus by adaptation to heparan sulfate-dependent infectivity: a model for rational arboviral vaccine design.
    Gardner CL; Hritz J; Sun C; Vanlandingham DL; Song TY; Ghedin E; Higgs S; Klimstra WB; Ryman KD
    PLoS Negl Trop Dis; 2014 Feb; 8(2):e2719. PubMed ID: 24587470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA vaccine initiates replication of live attenuated chikungunya virus in vitro and elicits protective immune response in mice.
    Tretyakova I; Hearn J; Wang E; Weaver S; Pushko P
    J Infect Dis; 2014 Jun; 209(12):1882-90. PubMed ID: 24585894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Live-attenuated CHIKV vaccine with rearranged genome replicates in vitro and induces immune response in mice.
    Tretyakova I; Joh J; Gearon M; Kraenzle J; Goedeker S; Pignataro A; Alejandro B; Lukashevich IS; Chung D; Pushko P
    PLoS Negl Trop Dis; 2024 Apr; 18(4):e0012120. PubMed ID: 38648230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infectious Chikungunya Virus (CHIKV) with a Complete Capsid Deletion: a New Approach for a CHIKV Vaccine.
    Zhang YN; Deng CL; Li JQ; Li N; Zhang QY; Ye HQ; Yuan ZM; Zhang B
    J Virol; 2019 Aug; 93(15):. PubMed ID: 31092567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential Transmission of Antiviral Drug-Resistant Chikungunya Viruses by
    Delang L; Yen PS; Vallet T; Vazeille M; Vignuzzi M; Failloux AB
    mSphere; 2018 Aug; 3(4):. PubMed ID: 30135220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A chikungunya fever vaccine utilizing an insect-specific virus platform.
    Erasmus JH; Auguste AJ; Kaelber JT; Luo H; Rossi SL; Fenton K; Leal G; Kim DY; Chiu W; Wang T; Frolov I; Nasar F; Weaver SC
    Nat Med; 2017 Feb; 23(2):192-199. PubMed ID: 27991917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel chikungunya vaccine candidate with an IRES-based attenuation and host range alteration mechanism.
    Plante K; Wang E; Partidos CD; Weger J; Gorchakov R; Tsetsarkin K; Borland EM; Powers AM; Seymour R; Stinchcomb DT; Osorio JE; Frolov I; Weaver SC
    PLoS Pathog; 2011 Jul; 7(7):e1002142. PubMed ID: 21829348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of Vaccines for Chikungunya Fever.
    Erasmus JH; Rossi SL; Weaver SC
    J Infect Dis; 2016 Dec; 214(suppl 5):S488-S496. PubMed ID: 27920179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conserved motifs in the hypervariable domain of chikungunya virus nsP3 required for transmission by Aedes aegypti mosquitoes.
    Göertz GP; Lingemann M; Geertsema C; Abma-Henkens MHC; Vogels CBF; Koenraadt CJM; van Oers MM; Pijlman GP
    PLoS Negl Trop Dis; 2018 Nov; 12(11):e0006958. PubMed ID: 30412583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chikungunya viruses that escape monoclonal antibody therapy are clinically attenuated, stable, and not purified in mosquitoes.
    Pal P; Fox JM; Hawman DW; Huang YJ; Messaoudi I; Kreklywich C; Denton M; Legasse AW; Smith PP; Johnson S; Axthelm MK; Vanlandingham DL; Streblow DN; Higgs S; Morrison TE; Diamond MS
    J Virol; 2014 Aug; 88(15):8213-26. PubMed ID: 24829346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential susceptibility & replication potential of Vero E6, BHK-21, RD, A-549, C6/36 cells &
    Sudeep AB; Vyas PB; Parashar D; Shil P
    Indian J Med Res; 2019 Jun; 149(6):771-777. PubMed ID: 31496530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deciphering the protective role of adaptive immunity to CHIKV/IRES a novel candidate vaccine against Chikungunya in the A129 mouse model.
    Chu H; Das SC; Fuchs JF; Suresh M; Weaver SC; Stinchcomb DT; Partidos CD; Osorio JE
    Vaccine; 2013 Jul; 31(33):3353-60. PubMed ID: 23727003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-Chikungunya Virus Monoclonal Antibody That Inhibits Viral Fusion and Release.
    Tumkosit U; Siripanyaphinyo U; Takeda N; Tsuji M; Maeda Y; Ruchusatsawat K; Shioda T; Mizushima H; Chetanachan P; Wongjaroen P; Matsuura Y; Tatsumi M; Tanaka A
    J Virol; 2020 Sep; 94(19):. PubMed ID: 32699087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chikungunya virus host range E2 transmembrane deletion mutants induce protective immunity against challenge in C57BL/6J mice.
    Piper A; Ribeiro M; Smith KM; Briggs CM; Huitt E; Nanda K; Spears CJ; Quiles M; Cullen J; Thomas ME; Brown DT; Hernandez R
    J Virol; 2013 Jun; 87(12):6748-57. PubMed ID: 23552427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and Use of Chikungunya Virus Replication Templates Utilizing Mammalian and Mosquito RNA Polymerase I-Mediated Transcription.
    Utt A; Rausalu K; Jakobson M; Männik A; Alphey L; Fragkoudis R; Merits A
    J Virol; 2019 Sep; 93(18):. PubMed ID: 31217251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.